Point72 Asset Management L.P. grew its stake in Sanofi (NASDAQ:SNY) by 4.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,057,400 shares of the company’s stock after buying an additional 42,400 shares during the period. Point72 Asset Management L.P.’s holdings in Sanofi were worth $52,299,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Credit Suisse AG boosted its stake in Sanofi by 18.6% during the 4th quarter. Credit Suisse AG now owns 104,623 shares of the company’s stock worth $5,084,000 after purchasing an additional 16,388 shares during the period. LPL Financial LLC boosted its stake in Sanofi by 3.1% during the 4th quarter. LPL Financial LLC now owns 75,055 shares of the company’s stock worth $3,647,000 after purchasing an additional 2,278 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in Sanofi by 1.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 88,014 shares of the company’s stock worth $4,277,000 after purchasing an additional 909 shares during the period. Stifel Financial Corp boosted its stake in Sanofi by 7.0% during the 4th quarter. Stifel Financial Corp now owns 249,514 shares of the company’s stock worth $12,123,000 after purchasing an additional 16,429 shares during the period. Finally, Tompkins Financial Corp acquired a new stake in Sanofi during the 4th quarter worth $44,000. Institutional investors and hedge funds own 7.89% of the company’s stock.
SNY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Sanofi in a research report on Friday, April 30th. Barclays reiterated an “equal weight” rating on shares of Sanofi in a report on Thursday, April 29th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and an average target price of $53.00.
Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Wednesday, April 28th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.14. The company had revenue of $8.59 billion for the quarter, compared to analyst estimates of $8.48 billion. Sanofi had a net margin of 17.33% and a return on equity of 24.12%. The business’s quarterly revenue was down 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.63 earnings per share. As a group, sell-side analysts anticipate that Sanofi will post 3.82 earnings per share for the current fiscal year.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Further Reading: What is a Buy-Side Analyst?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.